Recent Updates
Recently added Catalysts

HealthEquity, Inc

HQYFDA catalysts, PDUFA dates & pipeline intelligence
$103.63
▲ +0.17 · +0.16%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full HQY financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $72.7652W HIGH $110.26
Volume
674.40 K
Value Traded
69.59 M
Short % Float
7.38%
Days to Cover
7.8
+1.13%Week
+12.76%1 Month
-0.96%3 Month
+22.15%6 Month

Cash Data

Unlock HQY cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
8.57 B
EPS (TTM)
2.86
P/E Ratio
36.25
Ent. Value
9.25 B
Total Shares
82.72 M
Float Shares
80.54 M
Insiders
2.64%
Institutions
109.34%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every HQY catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

HQY Catalyst Timeline

Dated clinical, regulatory and corporate events for HealthEquity, Inc

Catalyst Timeline

Dated clinical, regulatory & corporate events for HealthEquity, Inc

1Total events
1Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage

Upcoming catalysts 1

T2Timing Guidance
Subscribe to view catalyst details
Unlock the full HQY catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How HQY actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all HQY historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

HealthEquity, Inc is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every HQY program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every HQY trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock HQY insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Rajasekar SunilOfficer (EVP Chief Prod & Strat Officer)Buy 108 53,405 held$90.33 10/15/2026
Unlock the full HQY insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Avidity Partners 0.4 % (-20 %) 1.55 M 16.90 K -33.2% ( -8.40 K)
Unlock every fund holding HQY
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in HQY
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see HQY ownership
Insider and institutional ownership, quarter by quarter.

HQY Short Interest

Shares sold short, counted twice a month.

7.38%
Short % of Float
of tradable shares sold short
5.9M
Shares Sold Short
-0.8% vs prior count
7.8 High
Days to Cover
trading days of normal volume to buy every short share back
763.6K
Avg Daily Volume
the average used for days to cover
Unlock HQY short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock HQY option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live HQY option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock HQY options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How HQY ranks across every disease it competes in

Competitive Position is a premium feature
See how HQY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

HQY News

-HQY
Nov 3, 2026
HQYGeneral
▲ +6.7%on this news

HealthEquity Schedules Third Quarter Earnings Release Date

HealthEquity, Inc. announced its third quarter earnings release for fiscal 2027, scheduled for December 1, 2026. Following the release, a conference call will be held at 4:30 p.m. ET to discuss the results. The company is a leader in health savings accounts and consumer-directed benefits.

Read more →
-HQY
Sep 30, 2026
HQYGeneral

HealthEquity Appoints Moody’s CFO Noémie Heuland to Board of Directors

HealthEquity has appointed Noémie Heuland, CFO of Moody's Corporation, to its Board of Directors effective September 24, 2026. Heuland will also participate in the Audit and Risk Committee and Cybersecurity and Technology Committee. Her expertise in finance and technology is expected to support HealthEquity's growth strategy and mission to enhance healthcare management for consumers.

Read more →
-HQY
Aug 27, 2026
HQYGeneral
▼ -10.6%on this news

HealthEquity Reports Second Quarter Ended July 31, 2026 Financial Results

HealthEquity reported strong financial results for the second quarter ended July 31, 2026, with a 10% increase in net income to $65.6 million and an 8% rise in revenue to $350.7 million. The company achieved a record Adjusted EBITDA margin of 48% and total HSA assets increased by 14%. Management has raised its fiscal 2027 guidance, reflecting confidence in ongoing growth.

Read more →
-HQY
Aug 3, 2026
HQYGeneral

HealthEquity Announces Second Quarter Earnings Release Date and Investor Conference Schedule

HealthEquity, Inc. has announced the release date for its second quarter fiscal 2027 earnings, set for August 27, 2026. Following the release, a conference call will be held to discuss the results. The company also plans to engage with investors at upcoming conferences, highlighting its position as a leader in health savings accounts.

Read more →
-HQY
Jun 8, 2026
HQYGeneral

One in Three Americans Delay Medical Care Due to Cost, HealthEquity Research Finds

HealthEquity's latest research reveals that over one-third of Americans delay medical care due to costs, highlighting ongoing healthcare affordability issues. The survey indicates that while understanding of benefits has improved, financial preparedness has declined. Notably, younger workers and those with chronic conditions are more affected. Health Savings Accounts (HSAs) appear to enhance financial readiness and security for users.

Read more →
-HQY
May 28, 2026
HQYGeneral

HealthEquity Reports First Quarter Ended April 30, 2026 Financial Results; Raises Guidance

HealthEquity reported first-quarter net income of $69.4 million, a 29 percent increase from the prior year. Adjusted EBITDA rose 17 percent to $164.5 million, while revenue grew 7 percent to $354.6 million. The company also raised its fiscal 2027 guidance and authorized an additional $1.0 billion for share repurchases. Total HSA assets reached $37.1 billion, reflecting a 19 percent year-over-year growth.

Read more →
-HQY
May 5, 2026
HQYGeneral

HealthEquity Announces First Quarter Earnings Release Date and Investor Conference Schedule

HealthEquity, Inc. announced the release date for its first quarter fiscal 2027 earnings, set for May 28, 2026. Following the earnings release, a conference call will be held to discuss the results. The company also plans to engage with investors at various upcoming conferences, emphasizing its commitment to transparency and investor relations.

Read more →
-HQY
Mar 30, 2026
HQYGeneral

HealthEquity Appoints Sanford Health CEO Bill Gassen to Board of Directors

HealthEquity has appointed Bill Gassen, CEO of Sanford Health, to its board of directors, effective March 26, 2026. Gassen will also participate in the Audit and Risk Committee and the Talent, Compensation and Culture Committee. His extensive experience in healthcare leadership is expected to bolster HealthEquity's efforts in helping consumers manage healthcare costs.

Read more →
-HQY
Mar 17, 2026
HQYGeneral

HealthEquity Reports Record Revenue, Earnings and New HSAs From Sales for Fourth Quarter and Year Ended January 31, 2026, Resulting in Raised Fiscal 2027 Outlook

HealthEquity reported record fiscal 2026 revenue of $1.31 billion and net income of $215.2 million. The company raised its fiscal 2027 outlook after adding one million new HSAs for the second consecutive year. Adjusted EBITDA grew 20% to $566.0 million, while total HSA assets increased 14% to $36.5 billion. Management expects 2027 revenue to reach between $1.405 billion and $1.415 billion.

Read more →
-HQY
Feb 17, 2026
HQYGeneral

HealthEquity Delivers Record Q4 and Standout Fiscal 2026 Sales Metrics

HealthEquity reported HSA assets reached $36.5 billion in fiscal 2026, a 14 percent increase from the prior year. The company also closed with 10.6 million HSAs, up 7 percent year over year. Fourth-quarter new HSA sales from accounts rose 17 percent compared to the same period last year. Management reaffirmed its guidance for the current and upcoming fiscal years.

Read more →
-HQY
Jan 12, 2026
HQYConferences/Events
▼ -10.2%on this news

HealthEquity Announces Fiscal Year 2027 Outlook Presentation at J.P. Morgan Healthcare Conference

HealthEquity, the largest HSA custodian in the U.S., has announced its fiscal year 2027 outlook, projecting revenues between $1.38 billion and $1.41 billion. The company reaffirmed its guidance for FY 2026 and highlighted its efforts in modernizing operations and enhancing security. HealthEquity will present these insights at the upcoming J.P. Morgan Healthcare Conference.

Read more →
-HQY
Dec 9, 2025
HQYGeneral

Young Americans Lead in HSA Adoption But Carry Heaviest Economic Burden, HealthEquity Research Finds

HealthEquity's Healthcare Affordability Pulse survey reveals that younger Americans, particularly Gen Z and Millennials, are leading in Health Savings Account (HSA) adoption while facing significant economic anxiety. Despite their proactive approach to healthcare savings, they report higher financial stress, which negatively impacts their workplace performance. The survey highlights the need for better education and employer support to enhance financial security.

Read more →
-HQY
Dec 3, 2025
HQYGeneral

HealthEquity Reports Third Quarter Ended October 31, 2025 Financial Results

HealthEquity reported third-quarter revenue of $322.2 million, a 7 percent increase from the prior year. Net income per diluted share rose to $0.59 from $0.06 a year ago. Non-GAAP net income per diluted share increased 29 percent to $1.01. Total HSA assets grew 15 percent to $34.4 billion during the quarter.

Read more →
-HQY
Nov 13, 2025
HQYGeneral

HealthEquity to Enhance Member Experience with Agentic AI

HealthEquity, Inc. has announced the deployment of agentic AI capabilities to enhance member experience. This technology aims to provide personalized support through natural conversations across various channels. The initiative is part of a broader commitment to leveraging technology for improved member outcomes, with a phased rollout beginning in November 2025. HealthEquity has previously implemented several AI-powered solutions to streamline processes and enhance customer engagement.

Read more →
-HQY
Nov 5, 2025
HQYGeneral

HealthEquity Announces Third Quarter Earnings Date

HealthEquity, Inc. (NASDAQ: HQY) has announced the release date for its third quarter fiscal 2026 earnings, set for December 3, 2025. Following the earnings report, management will host a conference call to discuss the financial results. The company administers HSAs for over 17 million accounts, emphasizing its commitment to enhancing consumer healthcare.

Read more →
-HQY
Oct 14, 2025
HQYGeneral

HealthEquity Introduces GLP-1 Telehealth and Direct HSA Enrollment Platforms

HealthEquity has launched two new initiatives aimed at improving access to affordable healthcare solutions. The first is a GLP-1 telehealth platform that connects HSA members with weight management medications. The second is a direct HSA enrollment platform, allowing individuals to open HSAs directly, particularly benefiting those newly eligible under recent ACA changes.

Read more →
-HQY
Sep 25, 2025
HQYGeneral

HealthEquity Strengthens Executive Leadership Team with Strategic Appointments to Drive Growth and Innovation

HealthEquity, Inc. has appointed Mukund Ramachandran as Chief Marketing Officer and Garett Kitch as Senior Vice President of Client Sales & Relationship Management. These appointments aim to enhance the company's strategic vision and capitalize on new market opportunities following recent federal legislation that expands HSA eligibility. The leadership changes are expected to strengthen HealthEquity's market position and drive innovation.

Read more →
-HQY
Sep 2, 2025
HQYGeneral
▲ +7.5%on this news

HealthEquity Reports Second Quarter Ended July 31, 2025 Financial Results

HealthEquity reported second quarter revenue of $325.8 million, a 9% increase from the prior year period. Net income rose 67% to $59.9 million, while non-GAAP net income grew 24% to $94.6 million. Adjusted EBITDA increased 18% to $151.1 million. The company also repurchased 0.7 million shares for $66.0 million during the quarter.

Read more →
-HQY
Aug 29, 2025
HQYGeneral

HealthEquity's AI-Powered Tool Recognized for Innovation in Streamlining Benefits Education

HealthEquity's AI-powered tool, HSAnswers, has been recognized with several awards for its innovative approach to benefits education. Launched in October 2024, it provides personalized responses to consumer-directed benefits inquiries. The tool has facilitated numerous conversations, addressing critical questions about health savings accounts and other benefits. HealthEquity aims to further enhance HSAnswers with more sophisticated features.

Read more →

About HealthEquity, Inc

Draper, UT 2,814 employees healthequity.com
Headquarters15 WEST SCENIC POINTE DRIVE, DRAPER, UT, 84020
BIOPHARMAWATCH ELITE PLUS
Trade the next HQY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime